Prabotulinumtoxin A

CHEMBL4297229 Phase 4 Disetujui Unknown

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

Prabotulinumtoxin A is a botulinum toxin type A product that acts by inhibiting the release of acetylcholine at the neuromuscular junction through cleavage of the SNAP-25 protein, causing temporary, localized muscle paralysis. It is approved for the treatment of chronic migraine prophylaxis and cosmetic treatment of glabellar lines.

Area Terapeutik

Neurology Migraine

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Prabotulinumtoxin A is a botulinum toxin type A product that acts by inhibiting the release of acetylcholine at the neuromuscular junction through cleavage of the SNAP-25 protein, causing temporary, localized muscle paralysis. It is approved for the treatment of chronic migraine prophylaxis and cosmetic treatment of glabellar lines.

Yes, Prabotulinumtoxin A is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297229. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Mencari informasi yang ramah bagi pasien?

Prabotulinumtoxin A di PillFYI

Data Cepat

Tautan Eksternal

ChEMBL CHEMBL4297229

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.